Tekmira is a leader in the development of therapeutic agents based upon Nobel Prize winning breakthroughs in the field of gene silencing, known as RNA interference (RNAi). Tekmira's three lead RNAi product candidates target cholesterol management, cancer and Ebola infection. In addition to its pipeline of products, Tekmira also has collaborative partnerships with leading companies in the RNAi field.
Mar 6, 2014 at 1:30 PM PT
Tekmira Corporate Update and Year-End 2013 Results
Feb 25, 2014 at 4:00 PM TOK
AsiaTIDES Conference in Tokyo, Japan